This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Non daily dosing of atorvastatin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Nondaily dosing regimens of statins

  • intermittent low-dose statins is an option for lipid lowering therapy in statin intolerant patients

  • atorvastatin and rosuvastatin, are longer acting
    • they are therefore useful for nondaily dosing regimens

  • alternate day, three times a week, twice a week, and once a week regimens have been tried and results are positive

  • evidence from a small double-blind, placebo-controlled trial of 35 patients receiving atorvastatin, 10 mg daily, versus alternate day regimen showed LDL cholesterol reductions of 38% and 35%, respectively, without any myopathy

  • use in statin intolerant patients
    • in a small study of 51 statin intolerant patients, who received rosuvastatin, 5 or 10 mg on alternate days, 80% of patients had no recurrence of myalgia
    • once weekly rosuvastatin, 5-20 mg, resulted in a mean LDL cholesterol reduction of 29% among 8 intolerant patients without any incidence of myopathy

  • non-daily rosuvastatin and atorvastatin seem tolerable - the use of non daily statin dosing may help lower LDL cholesterol levels in patients with statin intolerance

  • checking effectiveness of non-daily statin dosing

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.